Synthetic anti-infectives biotech Recce Pharmaceuticals (ASX:RCE) has entered into a Cooperative Research and Development Agreement with the US Army Institute of Surgical Research.
The partnership focuses on evaluating Recce 327, a proprietary burn wound gel designed to neutralise lethal bacterial pathogens.
The collaboration arrives at a critical juncture for military and civilian healthcare alike. Burn wound infections remain a primary driver of mortality for trauma patients, a crisis compounded by the global surge in antimicrobial resistance.
By leveraging Recce’s synthetic compound, the USAISR aims to develop a high-efficacy treatment capable of bypassing traditional antibiotic failures.
"This agreement demonstrates the accelerating US government interest in R327 across multiple operational and therapeutic applications," stated James Graham, CEO of Recce Pharmaceuticals.